{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NAI", "query": { "intervention": "NAI" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NAI&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T16:02:34.605Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00867139", "title": "TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "TCAD", "type": "DRUG" }, { "name": "Zanamivir or Oseltamivir", "type": "DRUG" }, { "name": "Open label treatment with TCAD", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 7, "start_date": "2009-03", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2013-08-15", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867139" }, { "nct_id": "NCT06123182", "title": "Guided Episodic Future Thinking to Increase Physical Activity Adherence and Promote Healthy Brain Aging", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Exercise Training", "Aging" ], "interventions": [ { "name": "Episodic Future Thinking", "type": "BEHAVIORAL" }, { "name": "Episodic Recent Thinking", "type": "BEHAVIORAL" }, { "name": "Positive Affective Imagery", "type": "BEHAVIORAL" }, { "name": "Neutral Affective Imagery", "type": "BEHAVIORAL" }, { "name": "HIIT Exercise Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "45 Years to 65 Years" }, "enrollment_count": 160, "start_date": "2024-02-23", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06123182" }, { "nct_id": "NCT01314963", "title": "Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma", "Breast Cancer" ], "interventions": [ { "name": "Prototype intraoperative handheld gamma camera (pIHGC)", "type": "DEVICE" }, { "name": "Lymphoscintigraphy with intraoperative gamma probes (GP)", "type": "DEVICE" }, { "name": "radioactive Tc99M", "type": "RADIATION" } ], "intervention_types": [ "DEVICE", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2008-06", "completion_date": "2012-07-26", "has_results": true, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01314963" }, { "nct_id": "NCT07123727", "title": "A Study to Examine Anktiva for the Treatment of COVID-19.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long COVID Syndrome", "Long Covid 19" ], "interventions": [ { "name": "Anktiva", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2025-09-04", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07123727" }, { "nct_id": "NCT03520686", "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "NAI + Pembrolizumab", "type": "DRUG" }, { "name": "NAI + Nivolumab + Ipilimumab", "type": "DRUG" }, { "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab", "type": "DRUG" }, { "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2018-05-18", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 31, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520686" }, { "nct_id": "NCT06753474", "title": "A/Texas Flu Challenge", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Influenza Virus influenza A H3N2 strain", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 50, "start_date": "2025-02-04", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06753474" }, { "nct_id": "NCT00297050", "title": "Safety and Dose Study of Peramivir for Influenza Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Peramivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 100, "start_date": "2006-02-23", "completion_date": "2006-11-14", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00297050" }, { "nct_id": "NCT06239220", "title": "PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic Head and Neck Cancer", "Recurrent Head and Neck Cancer", "Metastatic Head-and-neck Squamous-cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "PD-L1 t-haNK", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "NAI", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-02-16", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06239220" }, { "nct_id": "NCT00334529", "title": "Alternative Oseltamivir Dosing Strategies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Oseltamivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2006-06-05", "completion_date": "2007-04-10", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 4, "location_summary": "Los Angeles, California • Palo Alto, California • Bethesda, Maryland + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00334529" }, { "nct_id": "NCT01231620", "title": "A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "Zanamivir", "type": "DRUG" }, { "name": "Placebo to match zanamivir", "type": "DRUG" }, { "name": "Oseltamivir", "type": "DRUG" }, { "name": "Placebo to match oseltamivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 626, "start_date": "2011-01-15", "completion_date": "2015-03-18", "has_results": true, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-09-03T16:02:34.605Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231620" } ] }